Pancerebellar Syndrome in an Elderly Female — Complete Clinical Approach

1. HISTORY TO ASK

Onset & Time Course (Most Critical for DD)

Presenting Complaint

• Gait unsteadiness, falls, veering to one side
• Slurred/scanning speech
• Double vision, oscillopsia
• Clumsiness of hands (writing, utensils, dressing)
• Swallowing difficulty (late feature)
• Dizziness or vertigo

Aetiological History — Key Questions in Elderly Female

• History of breast or ovarian cancer (anti-Yo antibodies), lung cancer (anti-Hu), gynaecological malignancy
• Weight loss, night sweats, lumps, menstrual changes (if relevant)
• Previous cancer screening results

• Known hypothyroidism (myxoedema ataxia)
• Coeliac disease or gluten sensitivity — GI symptoms (diarrhoea, bloating), family history
• Type 1 diabetes (anti-GAD ataxia)

• Alcohol consumption — daily quantity, duration
• Drug history: phenytoin, carbamazepine, phenobarbital, lithium, metronidazole, amiodarone, chemotherapy agents
• Dietary adequacy — thiamine (B1), B12, vitamin E intake

• Hypertension, diabetes, atrial fibrillation, smoking (cerebellar stroke risk)
• Sudden onset or stepwise progression

• Recent viral illness (post-infectious cerebellitis, though rare in elderly)
• HIV risk factors
• TB exposure

• Associated parkinsonism features: rigidity, bradykinesia, REM sleep behaviour disorder → MSA-C
• Autonomic dysfunction: orthostatic hypotension, urinary incontinence, constipation, impotence → MSA
• Family history of ataxia (late-onset SCA — SCA-6, SCA-2 possible even in elderly)

• Connective tissue disease history (SLE, Sjögren — autoimmune ataxia)

Functional Impact

• Falls and injuries
• Ability to walk, use stairs, self-care

2. EXAMINATION

General

• Nutritional status, BMI, signs of chronic alcoholism (spider naevi, parotid enlargement)
• Lymphadenopathy, breast masses → paraneoplastic screen
• Skin: telangiectasia (ataxia-telangiectasia — rare in elderly), rash, jaundice

Neurological Examination — Five Domains (SARA Scale)

• Scanning (cerebellar) dysarthria: slow, with irregular rhythm and undue separation of syllables
• Explosive or slurred speech

• Finger-nose test: intention tremor, dysmetria, past-pointing
• Finger-chase test: overshoot/undershoot
• Dysdiadochokinesis (rapid alternating pronation/supination)
• Rebound phenomenon (Holmes rebound)
• Titubation (rhythmic head/trunk tremor)

• Heel-shin test: heel falls off the shin
• Lower limb intention tremor

• Wide-based, lurching, staggering gait — worsened on narrow base or tandem walking
• Romberg test: positive suggests sensory ataxia (consider combined disease)
• Truncal sway on sitting without back support
• Titubation at 3 Hz = anterior lobe atrophy

Associated Signs (Crucial for Aetiological Clues)

• Pyramidal signs (extensor plantars, brisk reflexes) → MSA-C, MS, spinocerebellar degeneration
• Extrapyramidal features (rigidity, bradykinesia) → MSA
• Autonomic: postural BP drop, anhidrosis
• Peripheral neuropathy (absent ankle jerks, reduced vibration/proprioception) → Friedreich's, paraneoplastic sensory neuropathy, B12/B1 deficiency
• Optic atrophy → Friedreich's, mitochondrial
• Pes cavus, scoliosis → Friedreich's (rare new presentation in elderly, but recessive forms)
• Cognitive impairment → MSA (minimal), CJD (rapid), posterior cerebellar atrophy

3. INVESTIGATIONS

Tier 1 — All Patients

Tier 2 — Based on Clinical Suspicion

• Paraneoplastic antibody panel: anti-Yo (PCA-1), anti-Hu (ANNA-1), anti-Ri, anti-Tr (DNER), anti-CASPR2, anti-NMDAR
• CT chest/abdomen/pelvis or PET-CT — occult malignancy (breast, ovary, lung)
• Mammography, CA-125, CA 19-9 as directed

• Anti-GAD antibodies (high titre > 2000 IU/mL → autoimmune ataxia)
• Anti-gliadin + anti-tissue transglutaminase antibodies (gluten/coeliac ataxia)
• Anti-TPO antibodies (Hashimoto encephalopathy / SREAT)
• ANA, ANCA, anti-dsDNA if systemic autoimmune suspected

• Serum alpha-fetoprotein (elevated in ataxia-telangiectasia)
• Serum cholesterol (cerebrotendinous xanthomatosis)
• Lactate, pyruvate (mitochondrial disease)

• Cell count, protein, glucose
• Oligoclonal bands (MS)
• 14-3-3 protein → CJD
• CSF paraneoplastic antibodies (when serum negative but suspicion high)
• CSF anti-GAD, anti-gliadin (when serum equivocal)

• CANVAS screen (RFC1 repeat expansion) — onset >45 years without family history
• FXTAS (fragile X tremor-ataxia syndrome — females can be affected; FMR1 CGG repeat)
• Spinocerebellar ataxia panel (SCA-1, 2, 3, 6, 7) if family history
• Whole-exome/genome sequencing if no diagnosis reached

• Nerve conduction studies + EMG — peripheral neuropathy (Friedreich's, paraneoplastic sensory neuronopathy, B12)
• VEPs, SSEPs — MS, mitochondrial

4. DIFFERENTIAL DIAGNOSIS

Most Important / Common

Autoimmune / Metabolic

Structural / Infectious / Other

Diagnostic Workflow

Key Clinical Pearl for Elderly Females

Paraneoplastic cerebellar degeneration must be actively excluded — it affects predominantly women with breast or ovarian cancers, evolves rapidly (weeks to months), and can precede cancer detection by years. Anti-Yo antibodies are the signature; PET-CT is essential even when structural imaging is negative. — Adams and Victor's Principles of Neurology, 12th Ed.; Bradley and Daroff's Neurology in Clinical Practice

Young-Onset Dementia (YOD) — Complete Clinical Approach

1. HISTORY

Presenting Cognitive Complaint

Onset & Progression

• Acute / subacute (days–weeks): autoimmune encephalitis, prion disease (CJD), CNS vasculitis, toxic/metabolic, NCSE
• Subacute (weeks–months): paraneoplastic, autoimmune, CJD, lymphoma, Wernicke's
• Gradual progressive (months–years): neurodegenerative (FTD, AD, HD, DLB), storage diseases, MS, mitochondrial
• Stepwise: vascular dementia
• Fluctuating: DLB (core feature), autoimmune, vascular

Aetiological Focused Questions

• Dementia in relatives — age of onset, type
• Huntington's disease — known family diagnosis? Chorea in relatives?
• Early-onset Alzheimer's (familial AD — PSEN1, PSEN2, APP mutations)
• FTD/ALS overlap — motor neuron disease in family (MAPT, PGRN, C9orf72)

• Alcohol — quantity, duration (alcohol-related brain damage, Wernicke-Korsakoff)
• Recreational drugs — chronic cannabis, stimulants
• Medications — lithium, methotrexate, anticholinergics, immunosuppressants

• Depression can mimic dementia ("pseudodementia") — previous depressive episodes, onset of mood change before or after cognitive decline
• Schizophrenia — long-standing psychosis with cognitive decline

• HIV status / risk factors
• Autoimmune disease: SLE (neuropsychiatric lupus), Sjögren's, antiphospholipid syndrome
• Thyroid disease, liver disease, renal failure, diabetes
• Epilepsy (NCSE, post-ictal state)
• Cardiac disease / stroke risk (vascular dementia)
• Down syndrome (early Alzheimer's)
• Head injury

• Weight loss, night sweats, fever, lymphadenopathy
• Rash (lupus, vasculitis)
• Joint pains, sicca symptoms (Sjögren's)
• Seizures (autoimmune encephalitis, CJD)

• Involuntary movements / chorea → Huntington's disease
• Rigidity, slowness → DLB, HD, CBD, Wilson's
• Tremor, Kayser-Fleischer rings → Wilson's disease (<45 yr, copper)
• Dystonia, dysarthria → Wilson's, neurodegeneration with brain iron accumulation (NBIA)
• Gait difficulty, falls → vascular, NPH, DLB, PSP

• REM sleep behaviour disorder → DLB (precedes dementia)
• Excessive daytime sleepiness → DLB, NPH

• Occupation (toxic exposures — heavy metals, solvents)
• Driving ability, job performance
• Social function, relationships

2. EXAMINATION

Cognitive Assessment

• Bedside cognitive tests: MoCA (Montreal Cognitive Assessment — preferred), MMSE, ACE-III
• Delineate which cognitive domains are affected (memory, executive, visuospatial, language, attention)
• Compare informant history with patient's own account (anosognosia → FTD, Alzheimer's)

General Examination — Aetiological Clues

Neurological Examination

• Vertical gaze palsy → PSP, Niemann-Pick type C
• Ophthalmoplegia → mitochondrial (MELAS), Wernicke's
• Optic atrophy → mitochondrial, MS
• Nystagmus → MS, Wernicke's, mitochondrial

• Chorea → Huntington's disease (pathognomonic), neuroacanthocytosis, SLE, antiphospholipid
• Parkinsonism (rigidity, bradykinesia, tremor) → DLB, HD (rigid variant), Wilson's, CBD, MSA
• Alien limb, cortical myoclonus, akinetic-rigid + cognitive → Corticobasal Degeneration (CBD)
• Pyramidal signs (spasticity, extensor plantars) → MS, vascular, metabolic leukodystrophies, HSP
• Lower motor neuron + dementia → ALS-FTD (C9orf72)
• Cerebellar signs → CJD, mitochondrial, prion, alcohol

• Apraxic / magnetic gait + urinary incontinence → Normal Pressure Hydrocephalus (NPH)
• Parkinsonian gait → DLB, HD-rigid, Wilson's
• Ataxic gait → CJD, mitochondrial, alcohol, Wernicke's

• Visual hallucinations → DLB (well-formed, animals/people)
• Disinhibition, altered eating behaviour, loss of empathy → FTD
• Catatonia → autoimmune (NMDAR), metabolic

3. INVESTIGATIONS

Tier 1 — All Patients (Mandatory)

Tier 2 — Targeted by Clinical Context

• Autoimmune encephalitis antibodies (serum + CSF): anti-NMDAR, anti-LGI1, anti-CASPR2, anti-AMPAR, anti-GABA-B — the most important treatable causes in young patients
• ANA, anti-dsDNA, ANCA, antiphospholipid antibodies (lupus, vasculitis)
• Anti-TPO, anti-thyroglobulin (Hashimoto encephalopathy / SREAT)
• Angiotensin-converting enzyme (ACE) → neurosarcoidosis

• Paraneoplastic antibody panel (anti-Hu, anti-NMDAR, anti-Yo, anti-Ri, anti-Ma2)
• CT chest/abdomen/pelvis or PET-CT → occult malignancy

• Serum copper, caeruloplasmin, 24-hr urine copper → Wilson's disease (mandatory in all <45)
• Serum ammonia → hepatic encephalopathy
• Lactate, pyruvate → mitochondrial disease
• Very long-chain fatty acids (VLCFA) → adrenoleukodystrophy
• Lysosomal enzyme panel → storage diseases (Gaucher, Niemann-Pick, GM2 gangliosidosis)
• Arylsulfatase A → metachromatic leukodystrophy

• CSF analysis: opening pressure, cells, protein, glucose, oligoclonal bands (MS), 14-3-3 protein, RT-QuIC (prion)
• CSF Real-time quaking-induced conversion (RT-QuIC) — high sensitivity for CJD
• CSF autoimmune encephalitis antibodies (when serum negative)

• FDG-PET: hypometabolism patterns — posterior temporal/parietal (AD), frontal (FTD), striatal (HD)
• Amyloid PET (florbetapir/florbetaben): early-onset AD confirmation
• DaTscan (123I-FP-CIT SPECT): dopaminergic deficit → DLB vs AD

• Huntingtin gene CAG repeat → Huntington's disease (if chorea + family history)
• FMR1 CGG repeat → Fragile X-associated neurological disorders (FXAND)
• Early-onset familial AD panel: PSEN1, PSEN2, APP
• FTD/ALS panel: MAPT, PGRN, C9orf72, TARDBP
• PRND / PRNP → familial CJD if rapid progressive dementia
• Whole-exome sequencing if no diagnosis reached

• EEG: periodic sharp wave complexes (CJD), non-convulsive status epilepticus, subclinical seizures
• NCS/EMG: peripheral neuropathy (B12, mitochondrial, paraneoplastic)

• Formal neuropsychological battery to characterise cognitive profile, assist in differential, and provide baseline

4. DIFFERENTIAL DIAGNOSIS

By Age Group (Critical Distinction)

Organised by Category

• Frontotemporal dementia (FTD) — most common in <60; behaviour variant (bvFTD) or language variant (PPA); ALS-FTD overlap (C9orf72)
• Early-onset Alzheimer's disease — familial (PSEN1 most common), posterior cortical atrophy variant
• Huntington's disease — autosomal dominant, chorea + psychiatric + cognitive, CAG >36
• Dementia with Lewy Bodies (DLB) — REM sleep behaviour disorder, visual hallucinations, fluctuating cognition, parkinsonism
• Corticobasal Degeneration (CBD) — alien limb, apraxia, asymmetric akinetic-rigid
• Progressive Supranuclear Palsy (PSP) — vertical gaze palsy, falls, subcortical dementia

• Autoimmune encephalitis (anti-NMDAR, anti-LGI1, anti-CASPR2) — most important treatable cause; must not miss
• Hashimoto encephalopathy (SREAT) — anti-TPO+, fluctuating, responds to steroids
• CNS vasculitis (primary or secondary to SLE, ANCA)
• Neuropsychiatric SLE
• Neurosarcoidosis
• MS — relapsing or progressive, white matter lesions, OCBs

• Sporadic CJD — rapidly progressive dementia + myoclonus + ataxia + periodic EEG, 14-3-3+, DWI cortical ribboning
• Variant CJD — young patients, psychiatric onset, thalamic DWI signal, prion-contaminated beef exposure

• Alcohol-related brain damage — Wernicke-Korsakoff (B1 deficiency), direct neurotoxicity
• B12 deficiency — subacute combined degeneration + cognitive decline
• Drug toxicity — lithium, methotrexate, immunosuppressants, chronic cannabis

• Wilson's disease — copper accumulation, <45, psychiatric + neurological + liver disease, KF rings
• Mitochondrial disease (MELAS, MERRF, POLG) — multisystem, stroke-like episodes, lactic acidosis
• Storage diseases — Gaucher (GBA), Niemann-Pick type C (NPC1/2), GM2 gangliosidosis — vertical gaze palsy, organomegaly
• Metachromatic leukodystrophy (MLD) — arylsulfatase A deficiency, white matter disease
• Adrenoleukodystrophy — X-linked, posterior white matter, VLCFA elevated
• Neurodegeneration with brain iron accumulation (NBIA) — basal ganglia iron on MRI

• Vascular dementia — stepwise decline, lacunar infarcts, white matter disease, vascular risk factors
• Normal Pressure Hydrocephalus (NPH) — Hakim's triad: gait apraxia + urinary incontinence + dementia; treatable with VP shunt
• Chronic subdural haematoma — head injury (may be forgotten), fluctuating, bilateral
• CNS lymphoma — periventricular ring-enhancing lesions, immunocompromised

• HIV-associated neurocognitive disorder (HAND) — must screen in all young patients
• Neurosyphilis — psychiatric + cognitive + tabes dorsalis, VDRL/TPHA
• Viral encephalitis (HSV, CMV, EBV) — acute onset, fever, seizures
• Whipple disease — rare, oculomasticatory myorhythmia + cognitive decline, gut symptoms
• Fungal / TB meningitis — immunocompromised, subacute

• Depression ("pseudodementia") — history of depression, onset of mood before cognition, cognitive symptoms worse subjectively than objectively, responds to antidepressants
• Schizophrenia — long-standing psychosis, cognitive impairment, young onset
• Functional cognitive disorder — internal inconsistency on testing

Red Flags for Urgent Assessment

Mnemonic for Treatable/Reversible Causes — "DEMENTIAS"

Core principle: In young-onset dementia, a thorough aetiological workup is mandatory — up to 20–30% of cases have a treatable or reversible cause that will be missed without systematic investigation. — Bradley and Daroff's Neurology in Clinical Practice

Young Patient with Dementia — Viva Style

• Acute/subacute (days–weeks) → autoimmune encephalitis, CJD, CNS vasculitis, NCSE, Wernicke's
• Months → paraneoplastic, lymphoma, prion, metabolic
• Gradual over years → FTD, early-onset AD, HD, storage diseases, MS

• Memory → AD
• Behaviour/personality change, disinhibition, loss of empathy → FTD
• Visuospatial → posterior cortical atrophy, DLB
• Fluctuating cognition + visual hallucinations → DLB

• Family history — dementia, chorea, MND? (HD, familial AD, FTD)
• Alcohol — quantity, duration (Wernicke-Korsakoff)
• Drug history — lithium, methotrexate, anticholinergics
• HIV risk factors, sexual history → HAND, syphilis
• Involuntary movements → Huntington's
• Psychiatric symptoms before cognition → variant CJD, anti-NMDAR, Wilson's
• Gait difficulty + urinary incontinence → NPH (treatable!)
• Weight loss, cancer history → paraneoplastic
• Autoimmune history — SLE, thyroid disease
• REM sleep behaviour disorder → DLB
• Seizures → autoimmune encephalitis, NCSE

• MRI brain (DWI + FLAIR + SWI + gadolinium)
• FBC, ESR, CRP, metabolic panel
• TFTs, B12, folate, thiamine
• Syphilis serology, HIV test (mandatory in young)
• Urine drug screen

• Anti-NMDAR, anti-LGI1, anti-CASPR2, anti-AMPAR, anti-GABA-B (serum + CSF)
• ANA, anti-dsDNA, ANCA, antiphospholipid antibodies
• Anti-TPO (Hashimoto encephalopathy)

• Copper + caeruloplasmin + 24-hr urine copper → Wilson's (mandatory <45)
• Lactate, pyruvate → mitochondrial
• VLCFA → adrenoleukodystrophy
• Lysosomal enzymes → storage diseases

• CSF 14-3-3, RT-QuIC (high sensitivity for CJD)
• EEG — periodic sharp wave complexes

• Huntingtin CAG repeat (if chorea/family history)
• PSEN1, PSEN2, APP (familial AD)
• C9orf72, MAPT, PGRN (FTD/ALS)

• FDG-PET — hypometabolism pattern
• DaTscan — if DLB suspected
• Amyloid PET — if early-onset AD suspected

1. Frontotemporal dementia
2. Huntington's disease
3. Multiple sclerosis
4. Autoimmune encephalitis
5. Neuropsychiatric lupus
6. Mitochondrial disease
7. Storage disease
8. Prion disease (CJD/vCJD)
9. Vasculitis

1. Alzheimer's disease
2. Vascular dementia
3. FTD
4. Alcohol-related dementia
5. DLB
6. Huntington's disease
7. Multiple sclerosis
8. Down syndrome–related AD
9. CBD / prion disease / Parkinson's dementia

• D — Drugs & toxins
• E — Endocrine (hypothyroid, Addison's)
• M — Metabolic (B12, thiamine, Wilson's, hepatic)
• E — Epilepsy (non-convulsive status)
• N — Normal pressure hydrocephalus
• T — Tumour / Trauma (SDH)
• I — Infection (HIV, syphilis, HSV encephalitis)
• A — Autoimmune/inflammatory encephalitis
• S — Structural (subdural, hydrocephalus)

• Weeks of progression → CJD, autoimmune encephalitis
• Fever + cognitive decline → encephalitis
• Seizures + confusion → NCSE, anti-NMDAR
• Chorea in a young patient → Huntington's, SLE
• Vertical gaze palsy → PSP, Niemann-Pick C
• Triad of gait + incontinence + dementia → NPH — refer for shunting
• Psychiatric onset in teens → vCJD, Wilson's, anti-NMDAR

In young-onset dementia, up to 30% have a treatable cause — a systematic workup starting with time course, cognitive profile, and targeted investigations (especially autoimmune, metabolic, genetic) is non-negotiable.